TY  - JOUR
AU  - Cámara, Rafael
AU  - Gozalbo, Irmina
AU  - Jurado, Manuel
AU  - Sanz, Jaime
AU  - Aragón, Belén
AU  - Grau, Santiago
PY  - 2017
DO  - 10.1007/s12325-017-0600-1
UR  - http://hdl.handle.net/10668/11502
T2  - Advances in therapy
AB  - Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). A new tablet formulation of...
LA  - en
KW  - Acute myelogenous leukemia
KW  - Cost-effectiveness
KW  - High-risk neutropenia
KW  - Invasive fungal disease
KW  - Myelodysplastic syndrome
KW  - Posaconazole
KW  - Adult
KW  - Aged
KW  - Antifungal Agents
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Fluconazole
KW  - Humans
KW  - Invasive Fungal Infections
KW  - Itraconazole
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Middle Aged
KW  - Models, Economic
KW  - Myelodysplastic Syndromes
KW  - Solutions
KW  - Spain
KW  - Tablets
KW  - Triazoles
TI  - Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
TY  - research article
VL  - 34
ER  -